Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also...
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 5966
- Registration Number
- NCT02849977
- Locations
- 🇺🇸
Axis Clinical Trails, Los Angeles, California, United States
🇺🇸PRI, LLC - Newport Beach - M3 Wake Research, Newport Beach, California, United States
🇺🇸South Florida Clinical Trials, Hialeah, Florida, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02431442
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02311673
- Locations
- 🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
🇺🇸University of California Irvine, Irvine, California, United States
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT02041195
Effects of RM-493 on Energy Expenditure in Obese Individuals
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01867437
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT01749137